((自动化翻译由路透提供，请见免责声明 ))
12月16日 - ** Edgewise Therapeutics 公司股价在盘前交易中上涨约 17% 至 32.28 美元
** 公司称其试验性遗传疾病药物在一项中期研究中达到了主要目标
** 该药物名为sevasemten，正在开发用于治疗贝克尔肌肉萎缩症，这是一种导致进行性肌肉无力和退化的罕见疾病。
** Sevasemten 有助于显著降低肌酸激酶的水平，肌酸激酶是一种与研究中骨骼肌损伤有关的酶--EWTX
** 截至上一交易日收盘，该公司股价在年初翻了一番多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.